ReviewEMBO molecular medicine2012
Molecular mechanisms of vascular effects of High-density lipoprotein: alterations in cardiovascular disease.
Review in EMBO molecular medicine, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 107 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
107 citing papers in PubMed, 1 synthesis or guideline pooled it, 209 citations in OpenAlex.
- Lipid profile and prognosis in patients with coronary heart disease: a meta-analysis of prospective cohort studies.BMC cardiovascular disorders · 2021Pooled it
- Impact of weight reduction on insulin resistance, adhesive molecules and adipokines dysregulation among obese type 2 diabetic patients.African health sciences · 2018Trial
- Determinants of HDL Cholesterol Efflux Capacity after Virgin Olive Oil Ingestion: Interrelationships with Fluidity of HDL Monolayer.Molecular nutrition & food research · 2017Trial
- Thermogenic adipocytes promote HDL turnover and reverse cholesterol transport.Nature communications · 2017Trial
- Trial
- Neutrophil extracellular trap suppression in rheumatoid arthritis patients treated with biologic therapy: a prospective observational study.Clinical rheumatology · 2026Article
- Observational
- Withaferin A, a candidate drug for lupus nephritis, confers renal protection via Pon1‑mediated attenuation of oxidative stress.International journal of molecular medicine · 2026Article
- Apolipoprotein A-I (CSL112) and Cardiovascular Outcomes in Atherosclerotic Cardiovascular Disease: A Scoping Review.Clinical cardiology · 2026Article
- Mechanisms, precision therapies, and technological frontiers in coronary atherosclerosis: a comprehensive review.Acta pharmacologica Sinica · 2026Review
- Dissociation Between Cholesteryl Ester Transfer Protein Mass and Activity in Coronary Artery Disease Patients with Elevated High-Density Lipoprotein Cholesterol: Implications for High-Density Lipoprotein Function and Residual Cardiovascular Risk.Anatolian journal of cardiology · 2026Article
- Protective Effect of Silymarin Against Paclitaxel-Induced Cardiotoxicity.Food science & nutrition · 2026Article
- Association of apolipoprotein A1 (rs 5069) genotyping with 25-hydroxyvitamin D deficiency and insulin resistance as a metabolic and genetic difference in obesity and type 2 diabetes mellitus.European journal of nutrition · 2026Article
- Associations between neutrophil-to-high-density lipoprotein cholesterol ratio and albuminuria: A cross-sectional study.The Journal of international medical research · 2026Article
- Association between very high HDL-C levels and cardiovascular mortality.European journal of medical research · 2026Article
- A guide to uraemic toxicity.Nature reviews. Nephrology · 2026Review
- The inflammatory marker SIRI acts as a statistical mediator between ApoB/ApoA1 ratio and atrial fibrillation, and combined biomarkers show higher discriminative ability for the presence of atrial fibrillation than single indicators.Frontiers in cardiovascular medicine · 2026Article
- Multiple facets of HDLs as modifiable risk factors in stroke-the good, the bad, and the ugly.Journal of lipid research · 2025Review
- Protective effects ofToxicology reports · 2025Article
- U-shaped Relationship between high-density lipoprotein cholesterol levels and intracranial aneurysm rupture: a retrospective cross-sectional study in the Chinese population.BMC neurology · 2025Article
47 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Low high-density lipoprotein (HDL)-cholesterol levels are associated with an increased risk of coronary artery disease (CAD) and myocardial infarction, which has triggered the hypothesis that HDL, in contrast to low-density lipoprotein (LDL), acts as an anti-atherogenic lipoprotein. Moreover, experimental studies have identified potential anti-atherogenic properties of HDL, including promotion of macrophage cholesterol efflux and direct endothelial-protective effects of HDL, such as stimulation of endothelial nitric oxide production and repair, anti-apoptotic, anti-inflammatory and anti-thrombotic properties. Studies in gene-targeted mice, however, have also indicated that increasing HDL-cholesterol plasma levels can either limit (e.g. apolipoprotein A-I) or accelerate (e.g. Scavenger receptor class B type I) atherosclerosis. Moreover, vascular effects of HDL have been observed to be heterogenous and are altered in patients with CAD or diabetes, a condition that has been termed 'HDL dysfunction'. These alterations in biological functions of HDL may need to be taken into account for HDL-targeted therapies and considering raising of HDL-cholesterol levels alone is likely not sufficient in this respect. It will therefore be important to further determine, which biological functions of HDL are critical for its anti-atherosclerotic properties, as well as how these can be measured and targeted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.